Merck, Roche test combo hep C therapy; Hunter Immunology acquired in reverse takeover;

 @FierceBiotech: Pfizer, GSK to supply hundreds of millions of pneumonia vaccines to GAVI. Report. GAVI to pay just $3.50 per vax.| Follow @FierceBiotech

 @JohnCFierce: Amgen has been making a a few deals on the cancer side (Biovex, Micromet this year). Hard to think there will be any dramatic changes. | Follow @JohnCFierce

 @FierceMedDev: FDA classifies voluntary physician advisory letter on Riata and Riata ST Silicone defib leads as Class I recall. Item | Follow@FierceMedDev

> Merck and Roche are teaming up to test a combo therapy for hepatitis C. Clinical trials will test Merck's oral drug Victrelis with Roche's Pegasys and Copegus and experimental drug HCV NS5B. Release | Report

> Valeant Pharmaceuticals said efinaconazole, a drug for fungal infections of the toenail, met the main endpoints in two Phase III trials. Report

> Probiomics is acquiring Hunter Immunology in a reverse takeover. Hunter is completing a Phase IIb trial of a therapeutic vaccine to treat COPD. News

> Shares of StemCells slid on the news the company plans to sell more common stock and warrants to raise money for product development and general purposes. Story

Pharma News

 @FiercePharma: CHMP recommends Roche's Zelboraf to treat BRAF mutation-positive metastatic melanoma. EC decision expected in Feb PR: Release | Follow @FiercePharma

> Generic drug companies to create private-sector drug shortage warning system. Story

> Gilead seeks sNDA for Truvada as HIV prevention. Report

> Bausch + Lomb eyes pharma ops expansion. Item

> CHMP gives thumbs up to Roche melanoma drug. Article

And Finally... Following an IOM report that found most chimpanzee testing useless, NIH director Francis Collins says the institute will no longer grant funding for applications that involve testing on chimps. Report

Suggested Articles

Biogen will develop a gene therapy with the goal of preserving and possibly restoring vision in patients with PRPF31-mutated retinitis pigmentosa.

A month after moving its COVID-19 antibody cocktail into human trials, Regeneron is testing the drug's ability to ward off COVID-19 infection.

Short reports are nothing new, but the aggressive “I’m coming after you” PR from Applied Therapeutics certainly is.